ArticleCureus2026
Non-traumatic Iliacus Muscle Hematoma During Anticoagulation Bridging in a Patient With Active Malignancy: A Case of Multifactorial Bleeding Risk.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with malignancy are at increased risk of bleeding due to tumor-related vascular fragility, chemotherapy-induced thrombocytopenia, impaired hepatic function, malnutrition, and systemic inflammation. Anticoagulation management in this population is further complicated by frequent medication changes, drug-drug interactions, poor oral intake, and acute illness, making bridging anticoagulation a particularly high-risk transition. We report a case of a non-traumatic iliacus muscle hematoma occurring during therapeutic-dose enoxaparin bridging in a patient with active metastatic malignancy, illustrating how multiple concurrent risk factors can precipitate clinically significant hemorrhage even when the international normalized ratio (INR) appears subtherapeutic or within range. A 67-year-old man with metastatic squamous cell carcinoma of the lung and larynx, atrial flutter on chronic warfarin therapy, and concurrent thrombocytopenia developed progressive anemia during hospitalization. Warfarin was held for a planned procedure, and bridging anticoagulation with therapeutic-dose enoxaparin was initiated. Imaging subsequently identified a 3.5 × 2.4 × 5.5 cm left iliacus muscle hematoma without evidence of trauma or active extravasation. The patient was managed conservatively with serial monitoring and individualized anticoagulation adjustments, resulting in hemoglobin stabilization and clinical improvement. This case reinforces the multifactorial nature of bleeding risk in patients with malignancy receiving anticoagulation and highlights that INR alone does not fully capture hemorrhagic risk when additional anticoagulants, thrombocytopenia, renal impairment, and cancer-related hemostatic alterations are present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.